IMPLENIA AG ● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
● In a short-term perspective, the company has interesting fundamentals.
Strengths
● The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at CHF 69.15 CHF in weekly data.
● The close medium term support offers good timing for purchasing the stock.
● Predictions on business development from analysts polled by Thomson-Reuters are tight. This results from either a good visibility into core activities or accurate earnings releases.
● The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.26 for the 2017 fiscal year.
● The company is one of the best yield companies with high dividend expectations.
● Over the past year, analysts have regularly revised upwards their sales forecast for the company.
● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
● The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
● Within the weekly time frame the stock shows a bullish technical configuration above the support level at 69.15 CHF
Weaknesses
● For the past seven days, analysts have been lowering their EPS expectations for the company.
● For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
